Clinical trials: Natural Killer Cell Malignancies
Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
This is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors…
- Trial name
- DUO-NK-NSCLC (NCT07467863)
- Testing
- Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive Care
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Natural Killer Cell Cytokine Production
Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy
This study will look at measuring the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in subjects being screened for colorectal cancer using colonoscopy.
- Trial name
- NCT02291198
- Testing
- NK Vue: NK cell activity in stimulated whole blood
- Where
- Canada
- Volunteers
- 1,081 people, healthy volunteers welcome
- Sponsor
- ATGen Canada Inc
Lymphoma, Non-Hodgkin
Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma
Nasal/nasal type NK-T-cell lymphoma is a rare and severe type of non-Hodgkin's lymphoma (NHL) more frequent in Asia than in western countries. When localised, radiotherapy seems to be the best treatment.
- Trial name
- NCT00283985
- Testing
- Kidrolase, Methotrexate, Dexamethasone
- Where
- 25 sites in France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Limoges
Carcinoma, Hepatocellular
CIK Treatment for HCC Patient Underwent Radical Resection
This is a randomized controlled study. About 200 patients with hepatocellular carcinoma who underwent radical resection will be included.
- Trial name
- NCT01749865
- Testing
- Cytokine-Induced Killer Cells
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Glioblastoma Multiforme
A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients
It is the primary objective of this study to show safety and tolerability for administration of the cell based immunotherapy ALECSAT to patients with Glioblastoma brain cancer.
- Trial name
- ALECSAT-GBM (NCT01588769)
- Testing
- ALECSAT cell based immunotherapy
- Where
- Denmark
- Volunteers
- 23 people
- Sponsor
- CytoVac A/S
Polycythemia Vera
Natural Killer Cells and Polycythemia Vera (Vaquez's Disease)
Natural Killer cells (NK) are pivotal cells of innate immunity, that sense defective expression of HLA class I molecules and are complementary to specific cytotoxic T lymphocytes.
- Trial name
- NCT01284712
- Testing
- blood sample
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Malignant Glioma
Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma
Malignant gliomas are very aggressive and among the most common of brain tumors. A diagnosis carries with it a median survival of approximately 12 months, with 90 - 95% of patients surviving less than 2 years.
- Trial name
- NCT01235845
- Testing
- Biological: DC activated CIK combined with DC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Qingdao University
NK T-Cell Lymphoma
Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens.
- Trial name
- NCT07457177
- Testing
- Golidocitinib + Pegaspargase + Anti-PD-1 mAb
- Volunteers
- 40 people
- Sponsor
- LIANG WANG
Lung Cancer, Neoplasms
Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC
A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.
- Trial name
- NCT03360630
- Testing
- Anti-PD-1 plus DC-CIK, Anti-PD-1 alone
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Capital Medical University
Pancreatic Cancer
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy.
- Trial name
- NCT03329248
- Testing
- ALT-803, ETBX-011, GI-4000
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ImmunityBio, Inc.
Nasal and Nasal-type NK/T-cell Lymphoma
Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ
The purpose of this study is to evaluate the efficacy and safety of DDGP regiment (gemcitabine，pegaspargase,cisplatin,dexamethasone) for patients with stage Ⅲ/Ⅳ Natural Killer (NK)/T Cell Lymphoma.
- Trial name
- CTTNKTL-Ⅲ/Ⅳ (NCT01501149)
- Testing
- DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase), Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Mingzhi Zhang
Acute Lymphoblastic Leukemia, Burkitt Lymphoma
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
This is a single center pilot study of a non-myeloablative umbilical cord blood transplant for the treatment of a hematological malignancy with a single infusion of T regulatory (Treg) given shortly after UCB transplantation.
- Conditions
- Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia
- Trial name
- NCT02991898
- Testing
- Infusion of Treg
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy.
- Conditions
- Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT07225439
- Testing
- Allogeneic NK cells, Rituximab, Tafasitamab
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Paolo Caimi, MD
Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
The first Part: recruiting untreated ENKL patients with extensive stage I or limited stage II disease (only referring to patients with the invasion of Waldeyer's ring and cervical lymph nodes) .
- Trial name
- NCT02560441
- Testing
- chemotherapy followed by radiotherapy, radiotherapy followed by chemotherapy, IPGDP regimen chemotherapy
- Where
- 5 sites in China
- Sponsor
- Chinese Academy of Medical Sciences
Allogenic Stem Cell Transplantation
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
This is a multicenter, parallel multicohort, phase 2, single-arm study for adjunctive treatment in participants with high-risk myeloid malignancies undergoing allogeneic HSCT.
- Trial name
- NCT05726682
- Testing
- SAR445419
- Sponsor
- Sanofi
Soft Tissue Sarcoma (STS)
Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study
This is a single-arm, open-label, non-blind, phase I/II clinical trial evaluating the safety and efficacy of umbilical cord blood natural killer (NK) cell in children with high-risk and relapsed/refractory soft tissue sarcoma…
- Trial name
- NCT06848582
- Testing
- umbilical cord blood NK cells
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
The Patients Undergoing Head and Neck Surgery Including Tumor Removal and Reconstruction With Flap
The Change of NK Cell Activity After Head and Neck Cancer Surgery
Cellular immunity can be changed after surgery and anesthesia. Tissue injury by surgical procedures significantly reduces the immune function in proportion to the degree of tissue injury.
- Trial name
- NCT02661776
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Yonsei University
Acute Myeloid Leukemia (AML)
Induced Pluripotent Stem Cells Derived Natural Killer Cells Therapy for Refractory and Relaps Acute Myelogenous Leukemia
This is a clinical study on the use of iNK cells for the treatment of refractory relapsed acute myeloid leukemia.
- Trial name
- iNK-r/r AML (NCT06702098)
- Testing
- iNK cells
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Guangzhou Ruixin Biotechnological Co., LTD
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS
The study examines the application of expanded natural killer cells (NK cells) following haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) for AML or MDS.
- Trial name
- NCT03300492
- Testing
- NK-DLI
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- University Hospital, Basel, Switzerland
Melanoma
High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma
The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of melanoma.
- Trial name
- NCT03007823
- Testing
- High-activity natural killer
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou